Sapporo Clinical Laboratory Inc. Stock

Equities

9776

JP3321100004

Drug Retailers

Delayed Japan Exchange 10:30:00 2024-04-23 pm EDT 5-day change 1st Jan Change
1,091 JPY +0.65% Intraday chart for Sapporo Clinical Laboratory Inc. -1.80% +8.99%
Sales 2022 19.11B 123M Sales 2023 20.13B 130M Capitalization 4.22B 27.26M
Net income 2022 1.04B 6.73M Net income 2023 568M 3.67M EV / Sales 2022 0.21 x
Net cash position 2022 409M 2.64M Net cash position 2023 1.24B 7.99M EV / Sales 2023 0.15 x
P/E ratio 2022
4.24 x
P/E ratio 2023
7.44 x
Employees 938
Yield 2022
1.77%
Yield 2023
1.82%
Free-Float 34.48%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 26, 2024. CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on March 26, 2024, has closed with 210,800 shares, representing 6.33% for ¥189.93 million. CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 232,100 shares, representing 6.97% for ¥209.12 million. CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan. CI
Sapporo Clinical Laboratory Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on May 30, 2022. CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on May 30, 2022 has closed with 22,700 shares, representing 0.67% for ¥29.21 million. CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 22,700 shares, representing 0.68% for ¥29.21 million. CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan. CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on February 28, 2022. CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on February 28, 2022, has closed with 53,700 shares, representing 1.58% for ¥69.11 million. CI
Sapporo Clinical Laboratory Inc. announces an Equity Buyback for 53,700 shares, representing 1.58% for ¥69.11 million. CI
Sapporo Clinical Laboratory Inc. authorizes a Buyback Plan. CI
Tranche Update on Sapporo Clinical Laboratory Inc.'s Equity Buyback Plan announced on June 21, 2021. CI
Sapporo Clinical Laboratory Inc.'s Equity Buyback announced on June 21, 2021, has closed with 16,300 shares, representing 0.48% for ¥25.92 million. CI
More news
1 day-0.37%
1 week+0.93%
Current month-0.55%
1 month+0.19%
3 months+6.30%
6 months+8.00%
Current year+7.89%
More quotes
1 week
1 074.00
Extreme 1074
1 111.00
1 month
1 069.00
Extreme 1069
1 111.00
Current year
1 000.00
Extreme 1000
1 111.00
1 year
983.00
Extreme 983
1 300.00
3 years
983.00
Extreme 983
1 720.00
5 years
983.00
Extreme 983
2 420.00
10 years
757.00
Extreme 757
2 624.00
More quotes
Managers TitleAgeSince
President 51 01-05-31
Chief Tech/Sci/R&D Officer - -
Director/Board Member 60 85-04-30
Members of the board TitleAgeSince
President 85 65-08-31
President 51 01-05-31
Director/Board Member 64 82-03-31
More insiders
Date Price Change Volume
24-04-23 1,091 +0.65% 400
24-04-23 1,084 +0.93% 300
24-04-22 1,074 -1.56% 1,100
24-04-19 1,091 -1.45% 800
24-04-18 1,107 -0.36% 1,300

Delayed Quote Japan Exchange, April 23, 2024 at 08:44 pm EDT

More quotes
SAPPORO CLINICAL LABORATORY INC. is a Japan-based company mainly engaged in the dispensing pharmacy business. The Company operates in three business segments. The Clinical Examination segment is engaged in the provision of clinical examination needed in medical examinations in hospitals. The Dispensing Pharmacy segment is engaged in operation of dispensing pharmacies, as well as wholesale of drugs and medicines. The Medical Equipment Sale and Maintenance segment is engaged in the sale and maintenance of high level medical equipment, general medical equipment, as well as physics and chemistry equipment. The others business is engaged in the development, sale and maintenance of software for clinical examination system.
Calendar
More about the company